PARIMATCH
26.6.2020 09:02:04 CEST | Business Wire | Press release
Sergey Portnov, CEO of Parimatch, took to the virtual stage yesterday at Collision at Home – a global virtual conference which brings together tech leaders and high-potential start-ups to discuss the issues affecting the tech industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005045/en/
During his speech, Sergey Portnov captivated Collison at Home’s 30,000 strong audience with his experience of transforming Parimatch from a physical bookmaker into a leading international tech and entertainment brand, giving viewers his top five tips on tech transformation.
On transforming into a tech business, Sergey Portnov said:
“At Parimatch we are obsessed with technology. We are a business built by businesspeople with management backgrounds, but now we have taken a major step to becoming a tech business – an endless journey with no destination.
“Tech can either be used as a tool, or can be used to describe a culture, a mindset. Previously at Parimatch, we used tech as a tool, but not anymore. Tech isn’t something which can be outsourced, it has to flow through your DNA. Only once you have this tech culture ingrained in your business will your company start to move ahead.”
Sergey’s top five tips on tech transformation:
Lesson 1 – Accept the sacrifice
“In the journey to tech transformation, you need to accept that you will lose things along the way. You may lose employees, customers, partners, maybe even revenue. Whilst this can be painful, this loss has to be accepted in order to transform and ultimately become stronger.”
Lesson 2 – Hire the best
“Don’t take the easy approach when it comes to hiring talent. We all know that it is people who make (or break) a business. Invest in the best people, and pay them a lot. People should be a serious financial investment. But don’t just pay them well, give them freedom in their role. Motivate them, and give them time to shine.”
Lesson 3 – Speed is of the essence
“For me, tech means speed. Every aspect of a tech business needs to be working at speed. The sports and betting industry are very fast paced, so we are able to surround our brand with that speedy energy. Be audacious and brave, create a culture of speed.”
Lesson 4 – Build company culture
“We are continually working on how to foster loyalty from our existing employees. We work with all of our people and spend time building culture and values. These aren’t just words on paper, we live them and people can see them in our actions. Values need to be authentic, and are essential to building a positive culture, and need to form the backbone of a business.”
Lesson 5 – Balance experience with ambition
“It is important to balance experience with ambition. When one outweighs the other, it causes problems. We were ambitious with little experience once upon a time, we made mistakes and learnt from them. On the other hand, you have businesses with lots of experience but no ambition, they have become complacent and are not likely to last into the future. The ideal balance is 51% ambition and 49% experience.”
A recording of Sergey Portnov’s speech can be viewed here: https://www.youtube.com/watch?v=CQ98g1U-doU&feature=youtu.be
-ENDS-
ABOUT PARIMATCH
Parimatch brings together technology, business and sport to deliver seamless entertainment powered by innovation. Founded in 1994, Parimatch has grown to become one of the largest betting companies in Europe and the CIS, and continues to explore new markets to enter. The business operates with a digital first mindset, and is constantly developing and improving the quality of its customer experience, which is enjoyed in 60 countries across the world. Parimatch’s winning team of brand ambassadors include Conor McGregor, Mike Tyson, Petr Yan and the Shevchenko sisters. Parimatch is also the title sponsor of the popular esports team Virtus.pro, and is the exclusive betting partner to UFC in the CIS region.
ABOUT COLLISION
Collision is “America’s fastest growing tech conference” created by the team behind Web Summit. In five years, Collision has grown from 2,500 to an expected 25,000 attendees from more than 120 countries. Attendees include CEOs of both the world’s fastest growing startups and the world’s largest companies, alongside leading investors and media.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200626005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom